温馨提示:本文中所涉及的信息旨在传递医药前沿信息和研究进展,不涉及诊疗方案推荐,临床上请遵从医生或其他医疗卫生专业人士的意见与指导。
封面图片:摄图网+稿定设计
责任编辑:觅健科普君
参考来源:
[1]Richard S. Finn.Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab(tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).[J].J Clin Oncol 41, 2023 (suppl 16; abstr 4010).
[2]姚帆,殷欣. 免疫检查点TIGIT/CD155对原发性肝癌免疫微环境的调控作用及应用展望[J]. 临床肝胆病杂志,2022,38(11):2632-2635.
[3]Masatoshi Kudo.Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation[J].J Clin Oncol 41, 2023 (suppl 16; abstr 4002).
[4]George L, Ann-Lii C, Bruno S, et al. Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab(T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol 41, 2023 (suppl 16; abstr 4004).
[5]Yoshiaki Nakamura. Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study[J].J Clin Oncol 41, 2023 (suppl 16; abstr 4007).
[6]Shubham Pant. Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC)[J].J Clin Oncol 41, 2023 (suppl 16; abstr 4008).
[7]Li Jingjing. A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.[J].J Clin Oncol 41, 2023 (suppl 16; abstr 4015).